The negotiated prices of 15 Medicare Part D drugs, which include several blockbusters, will go into effect in 2027.
Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the ...
In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...
Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
The global insulin delivery pen market is poised for remarkable growth, with its valuation projected to increase from USD ...
The best semaglutide dose for weight loss varies according to your starting weight, risks, and stage of treatment. Read to ...
Novo Nordisk (NYSE: NVO) and AstraZeneca (NASDAQ: AZN) are among the largest companies in the pharmaceutical industry. Both have generally produced strong financial results in 2024, but one wouldn ...
The biggest talking point in the pharmaceutical industry at the moment revolves around treatments known as glucagon-like peptide-1 (GLP-1) agonists. GLP-1 agonists are used to treat diabetes and ...
Novo Nordisk recently announced results for a new weight loss candidate, CagriSema. Data from the trial underwhelmed investors, and Novo stock is down almost 20% on the news. However, investors ...
Novo Nordisk should deliver a 24% CAGR over two years, driven by robust obesity drug market growth and improved operational performance, with an intrinsic value implying a 29% safety margin.
We came across a bullish thesis on Novo Nordisk A/S (NYSE:NVO) on Kontra Investments’ Substack by Kontra. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk A/S (NYSE ...